Cargando…
Update on anti-coagulation in atrial fibrillation
Atrial fibrillation (AF), the most common clinically relevant arrhythmia, affects 2.2 million individuals in the USA and 4.5 million in Europe, resulting in significant morbidity and mortality. Pharmacotherapy aimed at controlling both heart rate and rhythm is employed to relieve AF symptoms, though...
Autor principal: | Kreuzer, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3158856/ https://www.ncbi.nlm.nih.gov/pubmed/21816811 http://dx.doi.org/10.1093/qjmed/hcr107 |
Ejemplares similares
-
Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019) -
Heterogeneity in Preferences for Anti-coagulant Use in Atrial Fibrillation: A Latent Class Analysis
por: van Til, Janine, et al.
Publicado: (2020) -
Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation
por: Baylo, Alina, et al.
Publicado: (2023) -
Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation
por: Negreva, Mariya, et al.
Publicado: (2020) -
Atrial fibrillation: an update on management
por: McCallum, Craig J, et al.
Publicado: (2019)